SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

Evamplix

AGEN·AGENUS INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (Armenia only); Phase 3 (US/EU)
Time to market
Approved in Armenia (conditional, one-year authorization). No FDA or EMA approval timeline has been announced; the Phase 3 ROBBIN trial is expected to begin dosing in Q1 2027, meaning a potential US/EU approval, if successful, is likely several years away.
Why 4/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled within the next ~12 months. The Armenia approval is a small-market milestone, not a share-price binary. The next major catalyst is the Phase 3 ROBBIN trial start (Q1 2027), which is not a binary readout. Evamplix is a major value driver for Agenus, but without a near-term binary event the impact score is capped at 4.
Actionable Insight NEUTRAL

The next major catalyst is the start of the Phase 3 ROBBIN trial (first patient dosing expected Q1 2027), not a near-term binary event. The Armenia approval is a commercial milestone but not material for a US-listed stock. Watch for any FDA/EMA regulatory submission announcements or partnership deals, which could be share-price catalysts. The stock has already rallied ~195% YTD, reflecting optimism around BOT+BAL data.

Price Chart

Loading chart...

Executive Summary

Evamplix (balstilimab, BAL) is Agenus Inc.'s anti-PD-1 antibody, approved in Armenia in October 2026 as the brand Evamplix for use in combination with Botvymo (botensilimab, BOT) for previously treated MSS metastatic colorectal cancer. This is the drug's first marketing authorization anywhere, but it is conditional and valid for only one year in a small market. The drug remains investigational in the US and EU. Agenus is prioritizing the Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant high-risk stage II/III MSS colon cancer, with first patient dosing expected in Q1 2027 and a readout likely years away. Strong Phase 1b/2 data have been presented at SITC 2026 and ESMO 2026, showing durable survival benefit. The stock trades around $7.05 with a mean analyst price target of $26.33 (268% implied upside) and 8 Buy/Strong Buy ratings versus 1 Hold.

How It Works

Evamplix (balstilimab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune T cells. PD-1 acts as a brake on the immune system; by blocking it, balstilimab releases the brakes and allows the immune system to better recognize and attack cancer cells. It is designed to be used in combination with botensilimab (Botvymo), an anti-CTLA-4 antibody that targets a different immune checkpoint, together aiming to activate a broader anti-tumor immune response.

Trial Status

Evamplix (balstilimab) received its first marketing authorization in Armenia in October 2026, in combination with botensilimab, for previously treated MSS metastatic colorectal cancer. In the US and EU, the drug remains investigational. Agenus is preparing to launch the global randomized Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant high-risk stage II/III MSS colon cancer, with first patient dosing expected in Q1 2027. Multiple Phase 1b and Phase 2 trials have been completed or are ongoing across several tumor types, with data presented at SITC 2026 showing more than half of refractory MSS mCRC patients achieved long-term survival, and at ESMO 2026 showing 72% of dMMR colon cancer patients had no detectable cancer at surgery after six weeks of BOT+BAL.

The Two-Sided Case

▲ Bull Case4
Strong clinical data: Phase 1b C-800-01 trial showed more than half of refractory MSS mCRC patients achieved long-term survival (SITC 2026). At ESMO 2026, 72% of dMMR colon cancer patients had no detectable cancer at surgery after six weeks of BOT+BAL in the Phase 2 NEOASIS study.
Analyst consensus is overwhelmingly bullish: 8 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $26.33 (268% upside from the $7.15 close). HC Wainwright and Chardan Capital maintain Buy ratings.
Major institutional accumulation in Q2 2026: BlackRock doubled its position to 2.56M shares, Goldman Sachs added 1,325%, and Vanguard, Geode, and State Street all significantly increased holdings.
First marketing authorization (Armenia) validates the drug's regulatory pathway, even if in a small market. The company has generated $31.5M in Q3 2026 revenue and reported net income of $1.5M.
▼ Bear Case5
The Armenia approval is conditional and valid for only one year in a very small market, providing negligible commercial revenue. The drug remains unapproved by the FDA or EMA with no announced submission timeline.
The Phase 3 ROBBIN trial has not yet started enrolling (first patient expected Q1 2027), meaning a pivotal readout is likely years away. The company is a single-asset story dependent on BOT+BAL.
The PD-1 inhibitor market is intensely competitive, dominated by Merck's Keytruda and Bristol Myers' Opdivo. Balstilimab would need to demonstrate clear differentiation to gain meaningful market share.
The stock has already rallied ~195% year-to-date, suggesting much of the optimism may already be priced in. The company ended company funding for the later-line metastatic BATTMAN study to conserve cash for ROBBIN.
Q3 2026 revenue of $31.5M missed the $35M consensus estimate, and the company's ability to fund the Phase 3 program without further dilution is a concern.

Upcoming Catalysts

  • Phase 3 ROBBIN trial initiation (first patient dosing expected Q1 2027)
  • Potential additional country approvals for BOT+BAL beyond Armenia
  • Any FDA or EMA regulatory submission announcements
  • Future clinical data readouts from ongoing BOT+BAL studies

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AGENUS INC 8-K AGEN ·Originating report

Sources · 8

Hover a chip for the title
1 morningstar.com2 aol.com3 biospace.com4 seekingalpha.com5 msn.com6 pharmabiz.com7 cancernetwork.com8 businesswire.com